// App-Quantinova.ai

2881 : Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psoriatic Arthritis: Disease Activity and Remission in a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study

Researchers

Presenter

  • Laure Gossec

Principal Investigators

  • Laura Coates

  • Alice B. Gottlieb

  • Deepak Assudani

  • Barbara Ink

  • Jason Coarse

  • Oscar Irvin-Sellers

  • Dafna Gladman

Medical Centers

  • Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA

  • Sorbonne Université, oncology, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France

  • University of Oxford, Oxford, United Kingdom

  • Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, Philadelphia, PA

  • UCB Pharma, Slough, UK Slough United Kingdom

  • UCB Pharma, Raleigh, NC, USA, Raleigh, NC

  • Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada

Locations

  • United States

  • France

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • N/A

Biomarkers

  • Interleukin 17A

  • Malondialdehyde

Drug/Treatment

  • bimekizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved